phase iii volga: durvalumab tremelimumab enfortumab vedotin for neoadjuvant mibc
Published 1 month ago • 33 plays • Length 0:33Download video MP4
Download video MP3
Similar videos
-
1:12
ctdna clearance linked to improved outcomes in mibc neoadjuvant therapy: results from volga study
-
1:00
trial of durvalumab for bladder cancer
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
1:27
durigast: 2l folfiri plus durvalumab plus tremelimumab in gc or ge junction adenocarcinoma
-
3:16
phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer
-
4:38
danube trial: durvalumab alone or with tremelimumab for metastatic bladder cancer
-
1:07
dr. balar on impact of durvalumab plus tremelimumab in bladder cancer
-
2:18
btcrc-gu15-023: duart plus adjuvant durvalumab in bladder cancer
-
2:10
strong: fixed-dose durvalumab for utc
-
2:03
the evolution of bladder cancer treatment and the immuno-oncology era
-
4:04
perioperative treatment strategies for high-risk bladder cancer
-
3:46
perioperative management of advanced bladder cancer
-
4:11
durvalumab plus tremelimumab with radiation for muscle-invasive bladder cancer
-
6:57
phase ii trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
-
1:06
the mechanism of action of durvalumab in the treatment of urothelial bladder cancer
-
2:37
historic perspective on bladder cancer treatment
-
3:56
dose escalation of durvalumab tremelimumab in patients with metastatic urothelial cancer
-
2:13
inspire: bladder-sparing chemort with durvalumab in ln urothelial cancer
-
1:18
dr. powles on durvalumab in urothelial cancer